A5078678815- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Nuclear Receptors and Signaling
- Dementia and Cognitive Impairment Research
- RNA regulation and disease
- Autism Spectrum Disorder Research
- Alzheimer's disease research and treatments
- Ginkgo biloba and Cashew Applications
- Neurological diseases and metabolism
- Restless Legs Syndrome Research
- Genetic Neurodegenerative Diseases
- Genomics and Chromatin Dynamics
- Lysosomal Storage Disorders Research
- Botulinum Toxin and Related Neurological Disorders
- Amyotrophic Lateral Sclerosis Research
- Gene expression and cancer classification
- Cellular transport and secretion
- Obsessive-Compulsive Spectrum Disorders
- Systemic Lupus Erythematosus Research
- Mitochondrial Function and Pathology
- Epigenetics and DNA Methylation
- Histone Deacetylase Inhibitors Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Genomic variations and chromosomal abnormalities
- Advanced Neuroimaging Techniques and Applications
Stavanger University Hospital
2016-2025
University of Stavanger
2014-2024
Universidade Federal de Jataí
2024
Haukeland University Hospital
2006-2023
University of Bergen
2008-2023
Deaconess Hospital
2023
King's College London
2023
Imperial College London
2020
University of Aberdeen
2020
Centre for Movement Disorders
2008-2019
Little is known regarding the cognitive impairment in subjects with early, drug-naïve Parkinson disease (PD). The aim of this study was to explore proportion mild (MCI) and subtypes an incidence cohort untreated PD Southern Western Norway.A total 196 non-demented, drug-naive patients who were recruited after extensive search all new cases area 201 healthy control completed a battery neuropsychological tests verbal memory, visuospatial, attentional-executive functioning. Subjects classified...
The objective of this study was to assess the temporal relationship between changes in predominant motor symptoms and incident dementia Parkinson's disease (PD). A community-based sample 171 nondemented patients with PD followed prospectively examined at baseline after 4 8 years. subtype Parkinsonism classified into tremor-dominant (TD), indeterminate, or postural instability gait difficulty (PIGD) each visit, based on defined items Unified Disease Rating Scale, subscales II III. Dementia...
To investigate the prevalence, incidence, risk factors, and concomitants of Parkinson disease (PD)-associated psychosis (PDP) in a population-based prevalent cohort.Prospective longitudinal cohort study.Community-based study southwestern Norway.Two hundred thirty community-based PD patients were followed up prospectively for 12 years. Reassessments conducted at 4 8 years then annually.Severity PDP was measured by Unified Disease Rating Scale thought disorder (UPDRS-TD) item. Patients with...
<h3>Background:</h3> Neuropsychiatric symptoms are common in Parkinson’s disease (PD) and have important clinical consequences for patients, caregivers society. Few studies of neuropsychiatric early untreated PD exist. <h3>Objective:</h3> To explore the range, clustering correlates an incidence cohort subjects with PD. <h3>Methods:</h3> All cases incident identified during a 22 month period four counties Western Southern Norway were included. Standardised criteria used to diagnose The...
Mild cognitive impairment (MCI) is common in Parkinson disease (PD), but the prognostic value of MCI early PD unknown.To examine course and its progression to dementia an incident cohort.Prospective longitudinal cohort study.The Norwegian ParkWest study, ongoing population-based study incidence, neurobiology, prognosis western southern Norway.A 182 patients with monitored for 3 years.Serial neuropsychological tests attention, executive function, verbal memory, visuospatial skills were...
To identify independent risk factors of mortality in a community-based Parkinson disease (PD) cohort during prospective long-term follow-up.A prevalent sample 230 patients with PD from southwestern Norway was followed prospectively repetitive assessments motor and nonmotor symptoms 1993 to 2005. Information on vital status until October 20, 2009, obtained the National Population Register Norway. Cox proportional hazards models were applied predictors follow-up. Chronological age, Unified...
To examine the incidence, progression, and reversion of mild cognitive impairment in patients with Parkinson disease (PD-MCI) over 5 years.A population-based cohort incident PD underwent repeated neuropsychological testing attention, executive function, memory, visuospatial abilities at baseline (n = 178), 1 year 175), 3 years 163), 150). Patients were classified as PD-MCI diagnosed dementia according to published criteria.Thirty-six (20.2%) fulfilled criteria for baseline. Among those...
Abstract Background Several reports have identified different patterns of Parkinson's disease progression in individuals carrying missense variants GBA or LRRK2 genes. The overall contribution genetic factors to the severity and disease, however, has not been well studied. Objectives To test association between clinical features on a genomewide scale. Methods We accumulated individual data from 12 longitudinal cohorts total 4093 patients with 22,307 observations for median 3.81 years....
Common genetic variance in apolipoprotein E (APOE), β-glucocerebrosidase (GBA), microtubule-associated protein tau (MAPT), and α-synuclein (SNCA) has been linked to cognitive decline Parkinson's disease (PD), although studies have yielded mixed results.
<h3>Objective:</h3> To present the incidence of Parkinson’s disease (PD) in Norway and to explore gender influences on age at onset, as well severity pattern parkinsonism time diagnosis a representative drug naïve cohort with newly diagnosed PD. <h3>Methods:</h3> In four Norwegian counties comprising base population 1 052 075 inhabitants, multiple sources case ascertainment step diagnostic procedure were used establish patients incident PD high level accuracy. Of total 604 subjects referred...
To investigate risk factors and the rate of progression motor symptoms disability in a population-based cohort patients with Parkinson disease (PD).In all, 232 PD, derived from community-based prevalence study, were followed prospectively over an 8-year period. Follow-up examinations done 4 8 years after baseline, 144 participated at least one follow-up examination. Information on function was obtained using Unified Disease Rating Scale (UPDRS), Hoehn Yahr staging, Schwab England score....
<h3>Background</h3> Alzheimer9s disease (AD) pathology is found in a considerable portion of patients with Parkinson9s (PD), particularly those early dementia (PDD). Altered cerebrospinal fluid (CSF) levels amyloid-β (Aβ) and tau proteins have been PDD, intermediate changes for Aβ42 non-demented PD. The authors investigated whether AD-related CSF protein are altered relate to neuropsychological performance early, untreated <h3>Methods</h3> concentrations Aβ42, Aβ40 Aβ38 were measured by...
<b><i>Objective:</i></b> To evaluate if mental fatigue is a symptom that appears independently from other clinical features in patients with Parkinson disease (PD), and to study persistent over time these patients. <b><i>Methods:</i></b> In 1993, 233 PD were included community-based of followed prospectively 8 years. Fatigue was measured by combination seven-point scale parts the Nottingham Health Profile (NHP) at baseline after 4 addition, Severity Scale (FSS) used 2001. Population-averaged...
To examine associated demographic and clinical correlates the development of excessive daytime sleepiness (EDS) over 8 years in a community-based cohort patients with Parkinson disease (PD).A total 232 PD were included population-based prevalence study 1993. Patients followed prospectively reexamined after 4 years. At all visits, authors administered semistructured interviews to obtain information on variables. Standardized rating scales parkinsonism, depression, cognitive impairment used....
We investigated how health related quality of life (HRQL) changes over time in a population-based cohort patients with Parkinson's disease (PD), and which factors predict lower level HRQL these patients. Of 227 PD assessed at baseline followed prospectively, information on HRQL-status was obtained 111 subjects 4 years 82 8 after inclusion. measured by the Nottingham Health Profile (NHP). Analyses were conducted using generalized estimating equation models. The NHP total score (P < 0.001)...
<h3>Objective:</h3> To test in vivo the proposal from clinicopathologic studies that β-amyloid (Aβ) pathology shortens time to dementia Parkinson disease (PD), and explore utility of CSF Aβ related measures as early prognostic biomarkers an incident PD cohort. <h3>Methods:</h3> We assessed a population-based cohort 104 patients with who underwent lumbar puncture at diagnosis. analyzed concentrations Aβ42, Aβ40, Aβ38 using multiplexed immunoassay electrochemiluminescence (ECL) detection...
<h3>Objective</h3> To determine if any association between previously identified alleles that confer risk for Parkinson disease and variables measuring progression. <h3>Methods</h3> We evaluated the 31 variants A total of 23,423 visits by 4,307 patients European ancestry from 13 longitudinal cohorts in Europe, North America, Australia were analyzed. <h3>Results</h3> confirmed importance <i>GBA</i> on phenotypes. associated with development daytime sleepiness (p.N370S: hazard ratio [HR] 3.28...